## CNC: Centene Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 1.6% below STRENGTH zone (4.0-10.0%); PEG 1.61 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($37.09)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Voya Investment Management LLC Sells 557,418 Shares of Centene Corporation $CNC**
- Source: MarketBeat | 20251222T130213 | Neutral | Relevance: 100%
- Voya Investment Management LLC significantly reduced its stake in Centene Corporation (NYSE:CNC) by selling 557,418 shares, a 42.2% decrease, during the third quarter. Despite this, other major institutional investors like Vanguard Group Inc., Norges Bank, and State Street Corp. either increased or acquired new positions in Centene. Analysts maintain a "Hold" rating on Centene with a consensus price target of $38.44, following its recent earnings beat.

**2. Board of the Pension Protection Fund Invests $1 Million in Centene Corporation $CNC**
- Source: MarketBeat | 20251221T040738 | Somewhat-Bullish | Relevance: 100%
- The Board of the Pension Protection Fund has invested $1.003 million in Centene Corporation (NYSE:CNC), purchasing 28,100 shares in the third quarter. Centene exceeded earnings expectations with $0.50 EPS against a -$0.21 consensus and reported $49.69 billion in revenue, an 18.2% year-over-year increase. The stock, currently trading around $39.02, has a "Hold" consensus rating from analysts.

**3. UnitedHealth Group Stock (UNH) After Hours: Trump Premium Comments, New Audit “Action Plans,” and What to Watch Before the Next Market Open**
- Source: ts2.tech | 20251220T020817 | Somewhat-Bearish | Relevance: 67%
- UnitedHealth Group (UNH) stock experienced volatility due to President Trump's call for insurers to cut premiums and the company's release of 23 operational "action plans" from an independent review. The market is also closely watching the expiration of ACA subsidy expansions and the company's upcoming Q1 2026 review results for HouseCalls-related medical records. Investors will be focused on policy developments from Washington and the implementation of UnitedHealth's action plans as key drivers for Monday's market open.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 5 ($0.00M) |
| Sells | 2 ($2.58M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 11.6% (-2.8%)
- Blackrock Inc.: 9.2% (+0.3%)
- State Street Corpora: 4.3% (-7.7%)
- AQR Capital Manageme: 3.0% (+76.6%)
- Geode Capital Manage: 2.6% (-4.8%)

### Key Risks

1. Long-term trend broken: trading 7.8% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.61 elevated, pricing in significant growth expectations. Forward P/E 13.8x attractive for 43% earnings growth. Balance sheet: $1.1B free cash flow. Insider selling cluster ($2.6M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $19.6B |
| Beta | 0.48 |
| 52W Range | $25.08 - $66.81 |
| Short Interest | 3.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.61 |
| Forward P/E | 13.8 |
| Current P/E | 19.8 |
| YoY Growth | 43.0% |
| EPS Direction | RISING |

### Technicals

MRS_20 stable at 1.6% (minimal 5-day change). Below STRENGTH zone by 2.4pp (needs >4.0% for momentum thesis). MRS_5 at 0.5% confirms short-term momentum alignment. Below SMA200 (0.92x), long-term trend not supportive. RSI neutral at 58. OFD pattern: +MTL (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.61% (CS: 64) | Neutral |
| RSI_14 | 58.4 | Neutral |
| MACD Histogram | -0.07 | Bearish |
| vs SMA20 | 1.022x | Above |
| vs SMA50 | 1.078x | Above |
| vs SMA200 | 0.922x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $39.95
- **Stop Loss:** $37.09 (7.2% risk)
- **Target:** $42.81 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 419
- **Position Value:** $16,739.05
- **Portfolio %:** 16.74%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-02-03 (Est: $-1.19)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.16 | $0.50 | +404.3% |
| 2025Q2 | $0.21 | $-0.16 | -177.3% |
| 2025Q1 | $2.52 | $2.90 | +15.3% |
| 2024Q4 | $0.49 | $0.80 | +62.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*